Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
AstraZeneca
Baxter
Harvard Business School
Moodys

Last Updated: August 15, 2022

CLINICAL TRIALS PROFILE FOR MEKINIST


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for MEKINIST

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed GlaxoSmithKline Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed National Comprehensive Cancer Network Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed Novartis Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MEKINIST

Condition Name

Condition Name for MEKINIST
Intervention Trials
Melanoma 14
Advanced Malignant Solid Neoplasm 8
Recurrent Melanoma 7
Refractory Malignant Solid Neoplasm 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MEKINIST
Intervention Trials
Melanoma 27
Carcinoma 16
Neoplasms 16
Carcinoma, Non-Small-Cell Lung 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MEKINIST

Trials by Country

Trials by Country for MEKINIST
Location Trials
United States 531
Canada 18
United Kingdom 12
Australia 11
France 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for MEKINIST
Location Trials
Texas 30
California 24
Massachusetts 22
Pennsylvania 21
Ohio 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MEKINIST

Clinical Trial Phase

Clinical Trial Phase for MEKINIST
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MEKINIST
Clinical Trial Phase Trials
Recruiting 35
Active, not recruiting 30
Completed 11
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MEKINIST

Sponsor Name

Sponsor Name for MEKINIST
Sponsor Trials
National Cancer Institute (NCI) 42
Novartis 14
Novartis Pharmaceuticals 12
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MEKINIST
Sponsor Trials
Other 102
Industry 66
NIH 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Colorcon
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.